# BMT Core - Oregon Health and Science University (OHSU) Consortium

> **NIH NIH UG1** · OREGON HEALTH & SCIENCE UNIVERSITY · 2024 · $244,000

## Abstract

PROJECT SUMMARY
Allogeneic hematopoietic cell transplantation (HCT) is an essential therapeutic procedure used to
enhance the outcome of patients with acute myeloid leukemia (AML). Recent advances in alternative
donor transplantation and supportive care have allowed for a greater number of older adults and those
with co-morbidities to pursue potentially curative transplant procedures. In addition, the emerging era
of targeted therapy allows for the development of novel disease remission induction regimens as well as
transplant conditioning regimens that can enhance outcomes. However, relapse after allogeneic HCT
remains a major barrier to successful outcomes, with recent data suggesting that up to 50% of allogeneic
HCT failure and mortality relate to persistence or relapse of underlying disease. Recent advances in the
detection of minimal/measurable residual disease (MRD) have enhanced the capacity of identifying
some patients at high risk of relapse after HCT. Using information obtained by cytogenetics, fluorescence
in situ hybridization (FISH) and genomics, successful outcomes can still be achieved in a subset of
myeloid malignancy patients transplanted in the setting of morphologically active or MRD-detectable
disease at the time of transplant.
Recent observations have demonstrated that more intensive remission induction chemotherapy followed
directly by allogeneic transplantation can provide successful outcomes for patients with poorly
responsive, unfavorable AML after primary induction treatment. This proposal will investigate the
benefit of such aggressive intensive induction followed by immediate transplantation with myeloablative
conditioning for patients with intermediate and high risk AML, when compared to current standard
approaches. This effort will determine whether augmented remission induction therapy with early
transplantation using sensitive MRD assessment before and after transplant for myeloid malignancies
can be used to improve HCT outcomes with the most efficient health resource utilization. In so doing we hope
to establish the importance of more intensive induction chemotherapy in creating opportunities for the
best long-term transplant outcomes for the AML patient. Sensitivity of novel MRD assessments will be
available for study that could determine the need for novel interventions for post-HCT patient
management using a variety of emerging cellular and/or pharmacologic-targeted approaches.

## Key facts

- **NIH application ID:** 10936466
- **Project number:** 1UG1HL174405-01
- **Recipient organization:** OREGON HEALTH & SCIENCE UNIVERSITY
- **Principal Investigator:** RICHARD Thomas MAZIARZ
- **Activity code:** UG1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $244,000
- **Award type:** 1
- **Project period:** 2024-08-15 → 2031-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10936466

## Citation

> US National Institutes of Health, RePORTER application 10936466, BMT Core - Oregon Health and Science University (OHSU) Consortium (1UG1HL174405-01). Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/grant/nih/10936466. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*